Severe rebound multiple sclerosis (MS) activity is a life-threatening complication of natalizumab (NTZ) withdrawal, for which pathogenesis and treatment are still unclear. We report the immunological and pathological characterization of a case of central nervous system (CNS) inflammatory demyelination after NTZ discontinuation.
Objective:
To understand the pathophysiology of this neuroinflammatory condition.
Methods:
Antemortem blood and cerebrospinal fluid (CSF) analysis was compared with postmortem pathological studies, as well as with novel flow cytometry characterization of immune cells isolated from the CNS parenchyma.
Results:
Pathological analysis of the brain revealed the presence of innumerable active inflammatory demyelinating lesions typical of immunopathological pattern II. Monocytes/macrophages and B cells were enriched in the CNS parenchyma compared to the CSF. Numerous plasma cells were present in the lesions, but CD8 T lymphocytes were predominant in the parenchyma, as opposed to CD4 in the CSF. CNS-infiltrating lymphocytes expressed high levels of adhesion molecules, granzyme B (GzB), interferon-gamma (IFN-γ), and interleukin (IL)-17.
Conclusions:
Our results underline the differences in immune cell populations between the CSF and the CNS parenchyma, and suggest that aggressive immunosuppressive therapy targeting both T and B lymphocytes is warranted to control the overwhelming CNS inflammation.
GueguenARouxPDeschampsR. Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis. J Neurol Neurosurg Psychiatry2014; 85: 1038–1040.
2.
SorensenPSKoch-HenriksenNPetersenT. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol2014; 261: 1170–1177.
3.
Vidal-JordanaATintoreMTurC. Significant clinical worsening after natalizumab withdrawal: Predictive factors. Mult Scler2015; 21: 780–785.
4.
LenhardTBillerAMuellerW. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?Neurology2010; 75: 831–833.
5.
BeumeLADerschRFuhrerH. Massive exacerbation of multiple sclerosis after withdrawal and early restart of treatment with natalizumab. J Clin Neurosci2015; 22: 400–401.
JokubaitisVGLiVKalincikT. Fingolimod after natalizumab and the risk of short-term relapse. Neurology2014; 82: 1204–1211.
8.
CohenMMaillartETourbahA. Switching from natalizumab to fingolimod in multiple sclerosis: A French prospective study. JAMA Neurol2014; 71: 436–441.
9.
KapposLRadueEWComiG. Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS. Neurology2015; 85: 29–39.
10.
MichelLLarochelleCPratA. Update on treatments in multiple sclerosis. Presse Med2015; 44: e137–e151.
11.
LarochelleCCayrolRKebirH. Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system. Brain2012; 135: 2906–2924.
12.
MetzIRadueEWOterinoA. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol2012; 123: 235–245.
13.
HuangYPaxtonWAWolinskySM. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med1996; 2: 1240–1243.
14.
LucchinettiCBruckWParisiJ. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol2000; 47: 707–717.
15.
LarochelleCLecuyerMAAlvarezJI. Melanoma cell adhesion molecule-positive CD8 T lymphocytes mediate central nervous system inflammation. Ann Neurol2015; 78: 39–53.
16.
MullenKMGockeARAllieR. Expression of CCR7 and CD45RA in CD4+ and CD8+ subsets in cerebrospinal fluid of 134 patients with inflammatory and non-inflammatory neurological diseases. J Neuroimmunol2012; 249: 86–92.
17.
OkudaYOkudaMApatoffBR. The activation of memory CD4(+) T cells and CD8(+) T cells in patients with multiple sclerosis. J Neurol Sci2005; 235: 11–17.
ReboldiACoisneCBaumjohannD. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nature Immunol2009; 10: 514–523.
20.
ElovaaraILallaMSpareE. Methylprednisolone reduces adhesion molecules in blood and cerebrospinal fluid in patients with MS. Neurology1998; 51: 1703–1708.
21.
KivisakkPTrebstCLiuZ. T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: Implications for CNS trafficking. Clin Exp Immunol2002; 129: 510–518.
22.
LarochelleCAlvarezJIPratA. How do immune cells overcome the blood-brain barrier in multiple sclerosis?FEBS Lett2011; 585: 3770–3780.
23.
KebirHIferganIAlvarezJI. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol2009; 66: 390–402.
24.
TzartosJSFrieseMACranerMJ. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol2008; 172: 146–155.
25.
PlanasRMetzIOrtizY. Central role of Th2/Tc2 lymphocytes in pattern II multiple sclerosis lesions. Ann Clin Transl Neurol2015; 2: 875–893.
26.
RatzerRRomme ChristensenJRomme NielsenB. Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis. J Neuroimmunol2014; 276: 195–201.
27.
Martinez-CaceresEMBarrauMABrievaL. Treatment with methylprednisolone in relapses of multiple sclerosis patients: Immunological evidence of immediate and short-term but not long-lasting effects. Clin Exp Immunol2002; 127: 165–171.
28.
FoxRJCreeBADe SezeJ. MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study. Neurology2014; 82: 1491–1498.
29.
MartinelliVColomboBDalla CostaG. Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. Mult Scler2016; 22: 1506–1508.
30.
PattiFLeoneCZappiaM. Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: A case report. BMC Neurol2015; 15: 252.
31.
SepulvedaMLlufriuSBlancoY. Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: A case report. J Neurol2015; 262: 219–221.
32.
Lo ReMCapobiancoMRagoneseP. Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): A retrospective study from two Italian MS centers. Neurol Ther2015; 4: 147–157.
33.
MalucchiSCapobiancoMDi SapioA. Rituximab suppresses disease activity after natalizumab withdrawal: An exploratory study. Mult Scler2015; 21: 700.
34.
GiacominiPSRozenbergAMetzI. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med2014; 370: 486–488.
35.
Martin-BlondelGBauerJUro-CosteE. Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8(+) T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome. Acta Neuropathol2015; 129: 463–465.
